Roche announced today that it launched its Cobas Pulse system in select countries accepting CE mark approval in Europe.
Basel, Switzerland–based Roche designed its Cobas Pulse system to combine the form factor of a high-performance blood glucose meter with simple usability and expanded digital capabilities comparable to that of a smartphone. The platform joins Roche’s connected point-of-care solution portfolio.
According to a news release, it’s possible to use the Cobas Pulse system across a range of care settings needing timely and informed clinical decisions. In addition, Roche says it can simplify workflows for busy nurses and doctors and improve their ability to deliver bedside care.
Cobas Pulse includes digital health applications based on the Android operating system that perform clinically valuable functions. It has decision support and measurements of vital signs and digital biomarkers. Roche’s newest module in the Cobas Infinity Edge suite of software solutions, Smart, enables the selected apps within the platform.
The company has several partnerships, including Glytec, CardioSignal and SteadySense, and plans to seek CE IVDR and FDA clearance for the Cobas Pulse system in other markets throughout the coming year.
“Frontline health workers are under increasing pressure to not only accurately diagnose patients, but also make appropriate decisions on all aspects of disease management and patient care,” Roche Diagnostics CEO Thomas Schinecker said in the release. “Our commitment is to equip them with high-performance innovations that represent a real step-change in their working lives. We are pleased to introduce a truly novel solution that puts actionable clinical insights, and a near limitless range of digital capabilities for patient care, in the palms of their hands.”
